FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.739,30 +474,01 (+0,81%)
Achilles Therapeutics plc (ACHL)
Dopo ore:
| Chiusura precedente | 0,7801 |
| Aperto | 0,8000 |
| Denaro | 0,7775 x 200 |
| Lettera | 0,8431 x 200 |
| Min-Max giorno | 0,7925 - 0,8464 |
| Intervallo di 52 settimane | 0,7400 - 1,7600 |
| Volume | |
| Media Volume | 718.873 |
| Capitalizzazione | 33,35M |
| Beta (5 anni mensile) | 1,09 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,7400 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 2,83 |
GlobeNewswireAchilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice -LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC (“N
- GlobeNewswire
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T cell responses - - Strong cash position of $144 million supports operations through 2025 - LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered prec
- GlobeNewswire
Achilles Therapeutics to Present at Upcoming Conferences
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June: SAE Media Group Inaugural Cell and Gene Therapy Conference, London, United Kingdom Sergio Quezada, PhD, Chief Scientific Officer, will give an oral presentation titled “Targeting Clonal Neoantigens in Cancer” o
